Mood Effects of Serotonin Agonists: Depression

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT07017478
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 40 Years
Healthy Volunteers
Accepted

Interventions

  • LSD — DRUG
    The serotonin 2A receptor agonist LSD
  • Placebo — DRUG
    Distilled water

Study Details

This study will examine the effect of a low dose of the 5HT2A agonist LSD (26 µg), compared to placebo, on acute and protracted mood states in individuals with depression. The investigators will assess the relationship between mood-related symptoms and EEG as a neurophysiological marker.

Key Dates

Start date
Jun 9, 2025
Status verified
Jul 2025
Primary completion
Jun 1, 2026
Completion
Jun 1, 2026

Study Design

Enrollment
48 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER

Arms

  • Placebo Comparator: placebo
    distilled water (0.26 mL)
  • Experimental: LSD (26 micrograms)
    LSD tartrate in tasteless solution (0.26 mL)

Primary Outcome Measure

Acute Mood Measures [ Time Frame: Peak change (~2 hours post-drug) from pre-drug baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of ChicagoChicagoIllinois60637
Harriet de Wit (PRINCIPAL_INVESTIGATOR)

Find similar trials in Chicago, IL

By condition
Depression
By specialty
PsychiatryMental healthBehavioral health
By research site
University of Chicago· Chicago, IL

Related Studies